|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; Department of Medicine, Humboldt University, Charite Campus Mitte, Berlin, Germany
2 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
* To whom correspondence should be addressed. E-mail: u_tietge{at}yahoo.com.
Adiponectin is a novel adipocytokine negatively correlated with parameters of the metabolic
syndrome, such as body mass index (BMI), body fat mass (BFM), and circulating insulin levels.
Further, metabolic actions directly on the liver have been described. The aim of the present study
was to characterize circulating adiponectin levels, hepatic turnover, and the association of
adiponectin with key parameters of hepatic as well as systemic metabolism in cirrhosis, a catabolic
disease. Circulating adiponectin levels and hepatic turnover were investigated in 20 patients with
advanced cirrhosis. Hepatic hemodynamics (portal pressure, liver blood flow, hepatic vascular
resistance, indocyanine green half-life), body composition, resting energy expenditure, hepatic free
fatty acid and glucose turnover, circulating levels of hormones (catecholamines, insulin, glucagon)
and proinflammatory cytokines (IL-1
, TNF-
, IL-6) were also assessed. Circulating adiponectin
increased dependent on the clinical stage in cirrhosis compared with controls (15.2 ± 1.7 vs. 8.2 ±
1.1 µg/ml, resp., p<0.01), while hepatic extraction decreased. Adiponectin was negatively
correlated with parameters of hepatic protein synthesis (prothrombin time: r=-0.62, p=0.003,
albumin: r=-0.72, p<0.001), but not with transaminases or parameters of lipid metabolism. In
addition, circulating adiponectin increased with portal pressure (r=0.67, p=0.003), hepatic vascular
resistance (r=0.60, p=0.008) and effective hepatic blood flow (ICG half-life: r=0.69, p=0.001).
Adiponectin in cirrhosis was not correlated with BMI, BFM, parameters of energy metabolism,
insulin levels, hepatic FFA and glucose turnover, and circulating proinflammatory cytokines. These
results demonstrate that (i) adiponectin plasma levels in cirrhosis are significantly elevated, (ii) the
liver is a major source of adiponectin extraction, and (iii) adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism, but exclusively with reduced liver
function and altered hepatic hemodynamics.
This article has been cited by other articles:
![]() |
M. J. Bahr, J. Ockenga, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E199 - E206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakano, S. Tajima, A. Yoshimi, H. Akiyama, M. Tsushima, T. Tanioka, T. Negoro, M. Tomita, and T. Tobe A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin J. Lipid Res., July 1, 2006; 47(7): 1572 - 1582. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pagano, G. Soardo, W. Esposito, F. Fallo, L. Basan, D. Donnini, G. Federspil, L. A Sechi, and R. Vettor Plasma adiponectin is decreased in nonalcoholic fatty liver disease Eur. J. Endocrinol., January 1, 2005; 152(1): 113 - 118. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |